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Abstract
Background: Hematopoietic CD34+ stem cells are widely used in the clinical therapy of complicated blood
diseases. Stem cell factor Sall4B is a zinc finger transcription factor that plays a vital role in hematopoietic stem cell
expansion. The purpose of our current study is to further evaluate how Sall4B might affect the expansion of CD34+
cells derived from nonhuman primates.
Methods: Sall4B was overexpressed in nonhuman primate bone marrow-derived CD34+ cells via a lentiviral
transduction system. The granulocyte–erythrocyte–macrophage–megakaryocyte colony-forming unit (CFU) assay
evaluated the differentiation potential of primate CD34+ cells that were expanded with Sall4B. Furthermore, an
in-vivo murine system was employed to evaluate the hematopoietic potential of primate Sall4B-expanded CD34+ cells.
Results: Overexpression of Sall4B promoted ex-vivo nonhuman primate CD34+ cell expansion by 9.21 ± 1.94-fold on
day 9, whereas lentiviral transduction without Sall4B expanded cells by only 2.95 ± 0.77-fold. Sall4B maintained a
significant percentage of CD34+ cells as well. The CFU assay showed that the Sall4B-expanded CD34+ cells still
possessed multilineage differentiation potential. A study using nonobese diabetic/severe combined immunodeficiency
(NOD/SCID) mice in vivo revealed that Sall4B led to an increase in the number of repopulating cells and the 9-day-old
Sall4B-transduced CD34+ cells still possess self-renewal and multilineage differentiation capacity in vivo, which are
similar stemness characteristics to those in freshly isolated primate bone marrow-derived CD34+ cells.
Conclusions: We investigated the expansion of nonhuman primate bone marrow-derived CD34+ cells using the
Sall4B lentiviral overexpression approach; our findings provide a new perspective on mechanisms of rapid stem cell
proliferation. The utilization of Sall4B to expand CD34+ cells on a large scale through use of suitable model systems
would prove helpful towards preclinical trials of autologous transplantation.
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Background
Hematopoietic stem cells (HSCs) are rare stem cells that
have two defining features: self-renewal and multilineage
differentiation. They have the ability to differentiate into
specialized blood cells, including lymphocytes, red blood
cells, and platelets [1]. HSC transplantation can be an
important life-saving strategy in the clinical treatment of
a broad spectrum of disorders, such as lymphoma,
leukemia, and some other immune and genetic diseases
[2–4]. However, the full therapeutic potential of HSCs
has not been achieved. The HSC niche, described as
the microenvironment, contains stem cells, stem cell
progeny, osteoblasts, stromal cells, adipocytes, cytokines,
and chemokines. This niche controls the balance between
HSC self-renewal and differentiation [5]. However, under-
standing how niches modulate self-renewal and direc-
tional differentiation remains a challenge for scientists
worldwide [6].
It is essential to determine how transcription factors
affect HSC expansion, and to establish an efficient
method for enhancing the intrinsic self-renewing pro-
perties of HSCs ex vivo. The homeobox B4 (HoxB4)
gene belongs to the homeobox gene family and promotes
self-renewal and expansion of HSCs ex vivo [7–9]. The
manipulation of signaling pathways for genes such as
Notch and Wnt [10, 11] has also shown some effects on
ex-vivo HSC expansion. Sall4 is a zinc-finger transcription
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factor and a member of the Sall gene family, which was
originally cloned based on sequence homology to Dros-
ophila spalt (sal) [12–14]. In Drosophila, sal is a homeotic
gene that is essential for the development of posterior
head and anterior tail segments [15]. Recently, we de-
monstrated that lentiviral expression of Sall4 in human
bone marrow (BM) hematopoietic stem/progenitor cells
(HSPCs) was able to dramatically expand and enhance
their ability for long-term engraftment in nonobese dia-
betic/severe combined immunodeficiency (NOD/SCID)
mice [1, 16, 17]. During normal hematopoiesis, Sall4B
plays an important role in HSPCs by promoting self-
renewal and inhibiting differentiation [18]. Bmi-1 is a
member of Polycomb Repressive Complex 1 that has been
shown to be a critical regulator of hematopoiesis and
leukopoiesis [19–21]. A previous study showed that the
oncogene Bmi-1 is a direct target gene of Sall4B, where
Sall4B expression strongly correlates with Bmi-1 in pri-
mary acute myeloid leukemia (AML) and high levels of
H3–K4 trimethylation and H3–K79 dimethylation were
observed in the Sall4B binding region of the Bmi-1 pro-
moter [22]. Other researchers claimed that Sall4B may act
as either an activator or a repressor of Bmi-1 in a dose-
dependent fashion in hematopoiesis. In the presence of
extremely low Sall4B expression levels, HSPCs would
show loss of self-renewal. However, in the presence of very
high Sall4B expression levels, Bmi-1 might be suppressed,
and HSCs would lose their ability for self-renewal and
multilineage differentiation. HSPCs could maintain self-
renewal, multipotency, and differentiation only when
Sall4B expression was balanced appropriately [23].
The nonhuman primate is an important animal model
that can be applied to preclinical studies of stem cell
transplantation. Here, we demonstrated that Sall4B
overexpression could significantly enhance expansion of
nonhuman primate BM-derived CD34+ cells ex vivo, and
also in vivo in NOD/SCID mice. Furthermore, Sall4B
overexpression could maintain multilineage differentiation
capability and increase repopulating cell number as
demonstrated by ex-vivo granulocyte–erythrocyte–macro-
phage–megakaryocyte colony-forming unit (CFU-GEMM)
assay, and demonstrated in vivo in murine models. Our
findings would be vital for preclinical studies of nonhu-
man primate autologous CD34+ cell transplantation that
use the Sall4B overexpression approach on a large scale.
Methods
Ethics statement
All research involving animals was conducted according
to relevant national and international guidelines. Female
NOD/SCID mice (6–8 weeks old and 16.2–17.3 g) were
obtained from the Experimental Animal Center of
Soochow University (Suzhou, China). The experimental
protocols were approved by the Institutional Animal Care
and Use Committee of Soochow University (IACUC
permit number: SYXK(Su) 2014-0078).
The male cynomolgus primate (6 years old and 5.7 kg)
whose BM was used was obtained from the Medical
Primate Research Center of the Institute of Medical
Biology, Chinese Academy of Medical Sciences. The
primate was housed and bred according to the guide-
lines of the Experimental Animals Ethics Committee at
the Institute of Medical Biology, Chinese Academy of
Medical Sciences. The experimental protocol was also
reviewed and approved by the Yunnan Province Experi-
mental Animal Management Association (Permit Number
SYXK-YN No. 2014-0017) and the Experimental Animal
Ethics Committee of the Institute, which complied with
the humane regulations of replacement, refinement, and
reduction (3Rs). For BM sampling, nonhuman primate
was anesthetized with ketamine/acepromazine at a dosage
of 0.1 ml/kg body weight, intramuscularly, prior to hand-
ling and BM puncture (in accordance with institutional
standard operating procedures).
All surviving animals were also euthanized at the study
endpoint under anesthesia using a pentobarbital-based
euthanasia solution.
Animals
NOD/SCID mice were housed in individual stainless
steel cages in a SPF facility in Soochow University, with
a regulated temperature of 24 ± 2 °C, relative humidity
of 50 ± 10 %, and a 12-hour light cycle. Mice were sacri-
ficed by carbon dioxide (CO2) inhalation at 8 weeks post
transplantation. Peripheral blood (PB) and BM were
collected immediately after euthanasia.
The primate from which BM was obtained was housed
in an adjoining individual primate cage (130 cm× 53 cm×
80 cm) allowing social interactions, under controlled con-
ditions of humidity, temperature, and light (12-hour light/
dark cycle, 7:00 am–7:00 pm). Food and water were avail-
able ad libitum. Environmental enrichment consisted of
commercial toys. The primate was maintained at approxi-
mate free-feeding weight by postsession feedings of a nu-
tritionally balanced diet of high-protein banana-flavored
biscuits. In addition, fresh fruit and environmental enrich-
ment were provided daily. The primate was monitored
twice per day by the veterinarians. In cases of suffering,
the primate was treated with analgetic drugs.
Lentivirus production and titration
An optimized lentivirus packaging protocol was developed
to harvest high-titer green fluorescent protein (GFP)-
Sall4B lentivirus and GFP-control lentivirus [24]. As
shown in Fig. 1, 293 T cells seeded in a T75 flask were
used to package lentiviruses. Four high-quality vectors
(pMD2.G, pSPAX2, GFP-Sall4B plasmid, and GFP-control
plasmid) were obtained through a bacterial expression
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system. Sodium pyruvate and sodium butyrate that were
added to the media after DNA transfection significantly
improved the lentivirus yield. Three sample collections
were performed after transfection at 12, 36, and 60 hours.
Collected samples were filtered through a 0.2 μm filter
and centrifuged at 82,700 × g for 2 hours. Finally, the
lentivirus pellet was suspended with 200 μl IMDM. Lenti-
virus titer was determined with the Lenti-X™ qRT-PCR
Titration Kit (Clontech) according to the manufacturer’s
instructions. The lentivirus was aliquoted and stored
at –80 °C until use for transduction.
Nonhuman primate CD34+ cell isolation
CD34+ cells were enriched from fresh total mononuclear
cells (MNCs) of nonhuman primates with the magnetic-
activated cell sorting (MACS) immunomagnetic ab-
sorption column separation device, coupled with mouse
anti-primate CD34 antibody (BD, USA) and anti-mouse
IgG MicroBead (Miltenyi Biotec, Germany), according
to the manufacturer’s instructions. MNCs were obtained
from fresh nonhuman primate BM using density centri-
fugation with Ficoll-Hypaque Premium (GE Healthcare,
USA). The purity of CD34+ cells was verified using flow
cytometry, with anti-primate CD34 mAb conjugated
with phycoerythrin (PE; Immunotec, Canada) and the BD
FACSVerse flow cytometer (BD, USA).
Determination of optimal multiplicity of infection
Freshly isolated BM-derived primate CD34+ cells were
seeded in 24-well plates at a density of 2 × 105/ml. The
cells were cultured in StemSpan SFEM (Invitrogen,
USA) containing 5 % FBS and 1 % penicillin/streptomycin.
The media were supplemented with 100 ng/ml Flt-3 L
(PeproTech, USA), 20 ng/ml thrombopoietin (TPO)
(PeproTech, USA), and 100 ng/ml stem cell factor (SCF)
(PeproTech, USA). The next day, GFP-Sall4B lentivirus
was added with 5 μg/ml polybrene (Millipore, Billerica,
USA) to each well at different multiplicities of infection
(MOIs) of 0, 5, 20, 80, and 200 (n = 3). For controls, GFP-
control lentivirus was added to the CD34+ cells at a MOI
of 20. The cells were transduced overnight for 12 hours
and then recovered in fresh culture media. Media were
changed every other day for cell growth. On day 9, cells
were collected for cell count and flow cytometry in order
Fig. 1 Flow chart of lentivirus titration and production. Optimized lentivirus packaging protocol for production of high-titer lentivirus
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to determine the accurate number of total nucleated cells
and CD34+ cells in each group. Furthermore, western blot
analysis of Sall4B was performed to determine the Sall4B
protein expression level in each group.
Lentivirus transduction and cell expansion
The isolated BM-derived primate CD34+ cells were
cultured in 24-well plates overnight in StemSpan SFEM
supplemented with the mentioned three cytokines (SCF,
TPO, and Flt-3 L). GFP-Sall4B lentivirus and GFP-control
lentivirus were added at MOI of 20 on the following day,
supplemented with 5 μg/ml polybrene. Twelve hours later,
the media were replaced, and were subsequently changed
every other day until day 9. Cells were then collected
and prepared for cell count, flow cytometry, and study in
vivo.
Colony-forming unit assay
MethoCult H4230 methylcellulose media (Stem Cell
Technologies, Vancouver, Canada) were thawed overnight
at 4 °C in a refrigerator. Unexpanded primate CD34+ cells,
day 9 GFP-control, and GFP-Sall4B-expanded CD34+ cells
were prepared at the required final plating concentration
of 1 × 104 cells per dish. Duplicate cultures were prepared
with 1.1 ml cell suspension in each 35-mm dish. The cells
were incubated at 37 °C in 5 % CO2 with >95 % humidity
for approximately 16 days. The various CFUs, including
erythroid burst-forming unit (BFU-E), granulocyte colony-
forming unit (CFU-G), granulocyte–monocyte colony-
forming unit (CFU-GM), megakaryocyte colony-forming
unit (CFU-M), and CFU-GEMM, were analyzed with a
bright-field microscope on day 16 after the cells were
plated in MethoCult media. A colony with >100 cells was
counted as a positive colony.
NOD/SCID mice transplantation and repopulating assays
NOD/SCID mice received sublethal irradiation of 250 cGy
from a 60Co source (radioactive intensity: 0.38 Gy/min)
24 hours before cell transplantation. All mice were ran-
domly divided into five groups (n = 12 per group). The
negative control group was injected with 150 μl saline.
The unexpanded group was transplanted with 2 × 105
freshly isolated primate CD34+ cells. The other groups
were transplanted with day 9 expanded primate CD34+
cells from 2 × 105 starting cells (about 6 × 105 CD34+ cells
per mouse), day 9 GFP-control lentiviral transduced cells
from 2 × 105 starting cells (about 6 × 105 CD34+ cells per
mouse), or day 9 GFP-Sall4B lentiviral transduced cells
from 2 × 105 starting cells (about 1.8 × 106 CD34+ cells per
mouse). Saline or cells were transplanted by tail vein injec-
tion. PB samples were collected from the retro-orbital
plexus and BM samples were harvested from both fe-
murs/tibias of eight mice for each group in week 8 post
transplantation. PB and BM cells were stained with
antibodies and analyzed by flow cytometry. Briefly, mouse
blood samples were treated with red blood cell lysis buffer
to remove red blood cells while preserving the leukocytes.
Treated cells were then washed with phosphate-buffered
saline (PBS) and incubated with PE-CD45, allophycocya-
nin (APC)-CD14, or fluorescein isothiocyanate (FITC)-
CD20 antibodies (BD Pharmingen™) at room temperature
(RT) for 15 min in the dark. Cells were labeled with
mouse IgG isotype control monoclonal antibodies. The
physical conditions of the remaining four mice of each
group were observed for 6 months. The frequency of
SCID repopulating cells (SRC) was determined in limiting
dilution assays using the method of maximum likelihood
with L-CALC™ software (StemCell Technologies, USA)
from the proportions in the engrafted recipients (≥0.5 %
primate CD45+ cell engraftment, n = 30) measured in the
groups of mice transplanted with the progeny of dif-
ferent numbers of starting cells for groups of unex-
panded CD34+ cells, 9-day-old GFP-control lentivirus
transduced CD34+ cells, and 9-day-old GFP-Sall4B trans-
duced CD34+ cells.
Serially transplanted studies
Mouse BM cells were harvested from the femurs of
highly engrafted primary recipient mice 8 weeks after
transplantation. After removal of red blood cells, total
BM cells were transplanted into the secondary sublethally
irradiated (2.5 Gy, radioactive intensity: 0.38 Gy/min)
NOD/SCID mice (n = 8 per group). Eight weeks after
transplantation, the percentage of nonhuman primate
CD45+ cells in PB of the secondary recipient mice was
analyzed by flow cytometry.
Statistical analysis
One-way analysis of variance (ANOVA), followed by
Dunnett’s multiple comparison test, was used for compari-
sons among the various groups. Results were considered
statistically significant when P < 0.05.
Results
Titration of lentivirus packaging
Vectors for packaging were extracted with a plasmid kit
(QIAGEN, Germany). Purity of the single digested plas-
mids was assessed (Fig. 2a). The OD260/280 ratio was in
the range of 1.8–1.9, suggesting high-purity DNA extrac-
tion for lentivirus packaging. Packed lentiviral particles
were collected at 12, 36, and 60 hours, as shown in Fig. 1.
The 293 T cells showed abnormal size after 60 hours.
The high green fluorescence intensity (Fig. 2b) observed
after 48 hours indicated the high transfection efficiency
of 293 T cells. Various cell lines were used to test the
transduction efficiency of lentivirus, including 293 T
cells (Fig. 2c), HeLa cells, and endothelial cells (data not
shown). Strong fluorescence intensity indicated the high
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lentivirus titer, which was essential for CD34+ cell trans-
duction. Cell toxicity was avoided by determining the
specific MOI and transduction time of different cell
types. In general, the transduction time for carcinoma
cell lines (293 T and HeLa) was about 8–12 hours
with a MOI range of 1–10, which would be optimal
to reach high transduction efficiency and low cell tox-
icity. An average lentivirus titer of 4 × 108–5 × 108 IU/
ml could be obtained using the Lenti-X™ qRT-PCR
Titration Kit.
Nonhuman primate BM CD34+ cell isolation
Primate BM was obtained by tibial BM aspiration. About
6–8 ml of total BM could be gained in one aspiration
(3–4 ml per tibia). After MACS cell isolation, a high per-
centage of CD34+ cells was harvested. The ratio of
CD34+ cells to whole cells was 98.6 % as determined by
flow cytometry (Fig. 3a). The isolated CD34+ cells were
cultured in 24-well plates at a density of 2 × 105/ml and
recovered overnight. The purified cells were homogeneous
when observed by microscopy (Fig. 3b).
Fig. 2 Quality control of vectors and GFP expression in 293 T cells. a Four plasmids (psPAX2, pMD2.G, GFP-control expression vector, and
GFP-Sall4B expression vector) were amplified by bacteria amplification system and linearized by single digestion. The restriction endonuclease
recognition sites were Sac I, Not I, EcoR I, and EcoR I. b 293 T cells were monitored after 12 hours during the lentivirus packaging process (10 ×).
c GFP expression in 293 T cells 12 hours after lentivirus transduction (20 ×)
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Determination of optimal MOI for GFP-Sall4B lentivirus
The determination of optimal MOI was required due to
the toxicity of lentivirus and unknown side effects of
SALL4B protein overexpression in cells. Safe doses were
determined for GFP-Sall4B lentivirus group with MOI at
0, 5, 20, 80, or 200, and for GFP-control lentivirus group
with MOI at 20. The total nucleated cells and CD34+
cells in each group were observed on day 9, as shown in
Fig. 4a. As the MOI values of the GFP-Sall4B lentivirus
group increased from 0 to 20, the total cell expansion
fold increased. However, the fold expansion of total cells
and CD34+ cells decreased rapidly when the MOI value
was above 20. Western blot of Sall4B protein expression
was performed to observe whether Sall4B protein ex-
pression levels were accompanied by variations in MOI,
as shown in Fig. 4b. An increase of Sall4B protein in
total cell lysate was observed, indicating that the GFP-
Sall4B lentivirus efficiently transduced primate CD34+
cells.
Characterization of Sall4B-transduced CD34+ cells ex vivo
Primate CD34+ cells transduced with GFP-Sall4B at
MOI of 20, or with GFP-control lentivirus and saline
groups as controls, were cultured for 9 days. Typical
GFP-CD34+ cell clusters were observed (Fig. 5a, i and
ii). In contrast, cells were not formed in a large cluster
for control groups because only a small cluster or single
GFP cell was visible (Fig. 5a, iii and iv). The efficiency of
lentivirus transduction was 55 ± 4.87 % (Fig. 5b). On day
9, fold expansion was 14.4 ± 1.80 (total nucleated cells)
and 9.21 ± 1.94 (CD34+ cells) for the Sall4B-transduced
group, and was 6.26 ± 0.87 (total nucleated cells) and
2.95 ± 0.77 (CD34+ cells) for the GFP-control group
(Fig. 5d). In addition, the CD34+ cell ratio in the Sall4B
group was significantly higher than in the other two con-
trol groups (Fig. 5c). These results suggested that Sall4B
lentivirus was capable of maintaining the nonhuman
primate HSC properties, as well as enhancing cell prolifer-
ation. CFU assay examined the repopulation and multili-
neage differentiation of expanded CD34+ cells transduced
by Sall4B lentivirus on day 9. The Sall4B-transduced cells,
as well as freshly isolated primate CD34+ cells from day 0,
formed various colonies of CFU-GM, CFU-GEMM, and
BFU-E. However, significantly less colonies were formed
Fig. 3 Nonhuman primate BM CD34+ cell isolation. a Purity of isolated primate CD34+ cells. CD34+ cells were isolated via magnetic bead-based
antibody affinity purification as described in Methods. (Left) Scatter-plot representation of purified CD34+ cell preparations. Forward scatter (FSC)
and side scatter (SSC) were used to define gate MNC. (Right) (black curve) Negative control. The signal was detected using a fluorescently-labeled
APC and isotype-matched monoclonal mouse IgG control antibody. (Red curve) Purified cells incubated with fluorescently-labeled APC mouse
anti-nonhuman primate CD34 mAb. b Cell morphology of the freshly purified nonhuman primate CD34+ cells (20 ×)
Fig. 4 Determination of optimal MOI for GFP-Sall4B lentivirus in
primate CD34+ cells. Nonhuman primate BM CD34+ cells transduced
with GFP-control and GFP-Sall4B lentivirus at MOI of 0, 5, 20, 80, or
200 for 12 hours, and cultured for 9 days. a On day 9, total cell
number was counted and CD34+ proportions were obtained by flow
cytometry. The fold expansion of total nucleated cells and CD34+
cells was calculated based on the cell number on both day 0 and
day 9. Data presented as mean ± SD. ##P < 0.01, vs Sall4B at MOI = 0
group (total cell); **P < 0.01, ***P < 0.001, vs Sall4B at MOI = 0 group
(CD34+ cell). One-way ANOVA followed by Dunnett’s multiple
comparison test. b Sall4B polyclonal antibody was used to detect
Sall4B protein in cell lysates from all groups on day 9. β-actin was
used as the loading control. Sall4B protein bands were detected at
76 kDa in a dose-dependent manner, with MOI at 5, 20, 80, or 200.
GFP green fluorescent protein, MOI multiplicity of infection
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for the GFP-control group (Fig. 5e). The results indicated
that Sall4B lentivirus maintained stemness for expanded
nonhuman primate CD34+ cells.
In-vivo transplantation and repopulation assay in NOD/
SCID mice
The engraftment of nonhuman primate hematopoietic
cells was analyzed in five groups of irradiated NOD/SCID
mice. As shown in Fig. 6, differentiated primate cell clus-
ters were not detected by flow cytometry in the PB and
BM cells of negative control mice (saline) in week 8 post
transplantation. On the other hand, the primate CD45
marker was detected at 4.92 ± 1.24 %, 1.89 ± 0.43 %, 1.47
± 0.62 %, and 7.84 ± 2.31 % in the PB of groups trans-
planted with day 0 primate CD34+ cells, day 9 expanded
primate CD34+ cells, day 9 GFP-control lentiviral trans-
duced CD34+ cells, and day 9 GFP-Sall4B lentiviral trans-
duced CD34+ cells, respectively (Fig. 6a). Primate myeloid
lineage marker CD14 and lymphoid lineage marker CD20
could also be detected in the cell transplanted groups
(Fig. 6a). In mouse BM, primate CD45 marker was ex-
hibited at 5.27 ± 1.04 %, 2.73 ± 0.77 %, 2.45 ± 0.92 %, and
Fig. 5 Expansion and characterization of Sall4B-transduced primate CD34+ cells. a Bright-field and fluorescent images of nonhuman primate BM
CD34+ cells transduced with GFP-Sall4B lentivirus (i and ii, 20 ×) or GFP-control lentivirus (iii and iv, 20 ×) on day 9. The GFP-control CD34+ primate cell
clusters were distinguishable from GFP-Sall4B lentivirus groups. b Flow cytometry measured the proportion of GFP-positive cells transduced with
GFP-Sall4B or GFP-control lentivirus. c CD34+ percentage measured by flow cytometry on day 9 after transduction. **P < 0.01, GFP-Sall4B group vs
GFP-control group. d On day 9, total nucleated cells were counted and CD34+ cells were calculated from the total cell number and measured CD34+
percentage. ***P < 0.001, GFP-Sall4B group vs GFP-control group. e CFU colonies formed from CD34+ cells transduced with GFP-Sall4B lentivirus or
GFP-control lentivirus on day 9. Freshly purified CD34+ cells from day 0 were used as the positive control. The CFU colonies were counted on day 16
after cells were cultured in CFU MethoCult Media. **P < 0.01, vs freshly purified CD34+ cells from day 0. One-way ANOVA followed by Dunnett’s
multiple comparison test. GFP green fluorescent protein, w/o without, BFU-E erythroid burst-forming unit, CFU-GEMM granulocyte–erythrocyte–
macrophage–megakaryocyte colony-forming unit; CFU-GM granulocyte–monocyte colony-forming unit
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7.01 ± 1.18 % in day 0 primate CD34+ cells, day 9 ex-
panded primate CD34+ cells, day 9 GFP-control lentiviral
transduced CD34+ cells, and day 9 GFP-Sall4B lentiviral
transduced CD34+ cells, respectively (Fig. 6b). Primate
lineage markers CD14 and CD20 were also detected at dif-
ferent levels in four cell transplanted groups (Fig. 6b).
These results indicated that GFP-Sall4B transduced cells
had the ability to control their differentiation, repopula-
tion, and peripheral cell output, when compared with
GFP-control transduced cells or normal expanded CD34+
cells on day 9 in vivo. The cell population expanded by
Sall4B ex vivo for 9 days was revealed to have priority in
repopulating primate cells in NOD/SCID mice. Moreover,
the SRC frequency was found to be significantly enhanced
by stem cell factor Sall4B through limiting dilution ana-
lysis, which demonstrated a 2.27-fold increased SRC fre-
quency in mice that received 9-day-old SALL4B expressed
primate CD34+ cells (59 per 106 starting CD34+ cells)
compared with those receiving 9-day-old lentivirus con-
trol primate CD34+ cells (26 per 106 starting CD34+ cells),
and a 1.59-fold increased compared with those unexpanded
primate CD34+ cells (37 per 106 CD34+ starting cells) at
8 weeks post transplantation. These results suggested that
the Sall4B could be effective in expanding nonhuman pri-
mate CD34+ cells.
To further determine whether Sall4B-transduced cells
bear long-term engraftment, secondary BM transplanta-
tions were performed. Flow cytometry analysis of mouse
BM cells harvested from femurs in week 8 post secondary
transplantation showed that primate CD45+ cells could be
detected at 1.87 ± 0.73 %, 0.53 ± 0.22 %, 0.21 ± 0.12 %, and
2.05 ± 1.03 % in groups transplanted with day 0 primate
CD34+ cells, day 9 expanded primate CD34+ cells, day 9
GFP-control lentiviral transduced CD34+ cells, and day 9
GFP-Sall4B lentiviral transduced CD34+ cells, respectively
(Fig. 7). The result demonstrated that Sall4B-transduced
CD34+ cells could be successfully transplanted from one
animal BM to another on day 9. It was verified that
Sall4B-transduced CD34+ cells possessed long-term en-
graftable property.
Discussion
Multiple protein factors, including transcription factors,
epigenetic modifiers, and cell cycle regulators, play an im-
portant role in the regulation of HSC self-renewal [25, 26].
Our previous studies demonstrated that transcription
Fig. 6 Nonhuman primate cells in PB and BM of NOD/SCID mice transplanted with various stages of CD34+ cells. Eight weeks after intravenous
primate CD34+ transplantation in mice, primate CD45+, CD14+, and CD20+ cells were analyzed in the PB (a) and BM (b) of mice transplanted with
unexpanded primate CD34+ cells, 9-day expanded CD34+ cells, 9-day GFP-control transduced CD34+ cells, and 9-day Sall4B-GFP transduced CD34+
cells, respectively. Normal saline was injected as the vehicle control. Data represent mean ± SD, n = 16. **P < 0.01. One-way ANOVA followed by
Dunnett’s multiple comparison test. BM bone marrow, GFP green fluorescent protein, PB peripheral blood
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factor Sall4B was a robust stimulator for human and
mouse HSC expansion when combined with cytokines
(SCF, TPO, and Flt-3 L) [1]. TAT-Sall4B protein was able
to enhance the short-term and long-term engraftment of
human umbilical cord blood CD34+ cells in NOD/SCID
mice [27]. Although the genes between human and non-
human primate Sall4B are 97 % homologous, it is still
unknown whether human Sall4B possesses the same ex-
pansion capacity as nonhuman primate CD34+ cells. In
the current study, we have conducted ex-vivo expansion
of CD34+ cells from primate BM and xenogenic trans-
plantation in the NOD/SCID mouse model.
Our previous data also indicated that Sall4B enhanced
stem cell growth only in conjunction with the cytokines
(SCF and TPO) in its environment [1]. In the current
study, SCF, TPO, and Flt-3 L were employed as basic
cytokine cocktails along with lentiviral Sall4B to support
cell growth. We found that CD34+ cells were in a resting
state when lentiviral Sall4B was transduced without any
additional cytokines during the first 2-day or 3-day cul-
ture, which led to cell death. However, there were some
living cells observed on day 9. On the other hand, with
the addition of three cytokines, 3.14 ± 0.57-fold CD34+
cell expansion, along with 2.95 ± 0.77-fold expansion for
the GFP-control lentivirus group, and 9.21 ± 1.94-fold
expansion for the GFP-Sall4B lentivirus group were ob-
tained. This result indicated that GFP-control lentivirus
transduction would have no effect on cell proliferation,
and that lentiviral cells with Sall4B significantly en-
hanced primate CD34+ cell expansion as compared with
the other two control groups. The percentage of CD34+
cells in the GFP-Sall4B group was 9.12 ± 5.64 % higher
than either the GFP-control group or the cytokine only
group; thus implicating that Sall4B not only increased
CD34+ cell proliferation, but also maintained the stem-
ness of HSCs. This result was also confirmed by CFU-
GEMM assay, which suggested that day 9 culture cells
still possessed multilineage differentiation ability due to
Sall4B overexpression, as in freshly purified CD34+ cells.
We also found that an appropriately balanced level of
Sall4B expression was essential in maintaining HSC self-
renewal, multipotency, and differentiation. There were
two key factors that might influence Sall4B protein ex-
pression levels in primate cells: lentivirus MOI and trans-
duction time. By comparing the total cell and CD34+ cell
fold proliferation between each MOI group, GFP-Sall4B
lentivirus was added at different MOIs to determine opti-
mal MOIs,. The primate cell expansion was improved as
MOI increased from 0 to 20; however, cells could lose
expansion capacity when MOI continually increased from
20 to 200. This result was consistent with our previously
proposed study model [23]. The different lentivirus trans-
duction time points were also compared at this time. We
optimized for high transduction efficiency and low lenti-
viral cell toxicity; as a result, 12 hours was selected as the
optimal transduction time. Sall4B protein could be de-
tected in a dose-dependent fashion by western blot ana-
lysis, which indicated that Sall4B expression levels could
be controlled by optimizing the MOI and transduction
time.
Certain novel transcription factors showed the capabil-
ity to expand HSCs, such as HoxB4. However, lentivirus
transduction of these genes could cause expanded cells
to lose long-term repopulation potential [28]. Our sec-
ondary xenotransplantation results in mice showed that
Sall4B-transduced nonhuman primate CD34+ cells on
day 9 retained both short-term and long-term engrafta-
ble property, as in freshly isolated CD34+ cells. Further-
more, there was no evidence of leukemia in transplanted
mice more than 6 months after transplantation, indicat-
ing that the expanded Sall4B-transduced CD34+ cells
were safe in vivo.
We tried to purify TAT-Sall4B protein in bacteria [1]
and Sf9 insect cell expression systems [16, 29]. The pro-
tein yield was too low for studies in mice. GFP-Sall4B
lentivirus functioned as both transduced vector and
marker for verifying Sall4B efficacy on primate CD34+
cells in vivo. More efforts should be made to improve
Fig. 7 Secondary BM transplantation in NOD/SCID mice. Representative flow cytometric analysis of the mouse BM CD45+ cell population from
five groups in week 8 post secondary transplantation. NS normal saline, GFP green fluorescent protein
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the yield of TAT-Sall4B protein production on a large
scale.
The published human data were based on murine
models. As we all know, the overwhelming homology
between humans and primates make the primate model
a valuable one for preclinical studies, including HSC
transplantation. However, a transplant human cell into
nonhuman primate recipes is infeasible due to the inev-
itable immunological rejection. Thus, autotransplantation
is an alternative to evaluate the expanded HSC in non-
human primate model. This is the first study to show that
CD34+ cells derived from nonhuman primate could
be efficiently expanded by overexpressing Sall4B, which
would serve as a footstone for further preclinical studies
in nonhuman primate autologous transplantation and
clinical applications.
Conclusions
Nonhuman primate CD34+ cell expansion capability
could be effectively enhanced by Sall4B lentiviral overex-
pression, which provides a new perspective on mecha-
nisms of rapid stem cell proliferation. Additionally, it
would provide preclinical information that would be
helpful towards autologous transplantation in the clinic.
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